Apogee Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Apogee Therapeutics has a total shareholder equity of $801.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $823.7M and $22.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$816.20m |
Equity | US$801.48m |
Total liabilities | US$22.18m |
Total assets | US$823.66m |
Recent financial health updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Recent updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Financial Position Analysis
Short Term Liabilities: APGE's short term assets ($820.6M) exceed its short term liabilities ($21.6M).
Long Term Liabilities: APGE's short term assets ($820.6M) exceed its long term liabilities ($630.0K).
Debt to Equity History and Analysis
Debt Level: APGE is debt free.
Reducing Debt: APGE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APGE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: APGE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 117.9% each year